REVA Medical, Inc. ("REVA" or the "Company") completed its initial public offering of CDIs (CHESS Depository Interests) on December 17, 2010 and began trading on the Australian Securities Exchange ("ASX") on December 23, 2010, under the symbol "RVA." Ownership interests in REVA may be held in either CDIs or shares of common stock, but only CDIs may be traded on the ASX. Ten CDIs are equal to one share of common stock.
REVA is dedicated to developing minimally invasive medical devices that leverage its proprietary technologies. Guided by an executive management team with extensive product development experience and working closely with skilled interventional cardiologists in multiple countries, REVA's primary focus is the development of drug-eluting bioresorbable coronary scaffolds for the treatment of cardiovascular disease, the leading cause of death worldwide. Utilizing its stent designs and proprietary polymers, the Company designs its scaffolds to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The Company has conducted clinical studies of its scaffold technologies and its next generation scaffold, Fantom™, is in the development and testing phase. A total of 112 patients were enrolled in its most recent trial in Australia, Brazil, Europe, and New Zealand; they will be followed for a total of five years, with primary data to be obtained at nine and 12 months. First human implants of Fantom are planned for late 2014 at multiple centers in Brazil and Europe. REVA will require successful clinical results and regulatory approval before it can commercialize Fantom or any of its other products.
REVA is headquartered in San Diego, California.